Literature DB >> 2179227

Childhood leukemia: cooperative Berlin-Frankfurt-Münster trials in the Federal Republic of Germany.

J Ritter1, U Creutzig, A Reiter, H Riehm, G Schellong.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2179227     DOI： 10.1007/BF01612648

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  11 in total

Review 1.  Acute myelogenous leukaemia in children.

Authors:  S O Lie
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

2.  [The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)].

Authors:  G Henze; H J Langermann; J Brämswig; H Breu; H Gadner; G Schellong; K Welte; H Riehm
Journal:  Klin Padiatr       Date:  1981-05       Impact factor: 1.349

3.  Prognostic significance of Auer rods in childhood acute myelogenous leukemia: results of the studies AML-BFM-78 and -83.

Authors:  J Ritter; J Vormoor; U Creutzig; G Schellong
Journal:  Med Pediatr Oncol       Date:  1989

4.  Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update.

Authors:  H J Weinstein; R J Mayer; D S Rosenthal; F S Coral; B M Camitta; R D Gelber
Journal:  Blood       Date:  1983-08       Impact factor: 22.113

5.  [Risk groups in acute, non-lymphatic leukemia in childhood. Analysis of the results of the cooperative therapeutic studies AML-BFM 78 and 83].

Authors:  J Ritter; U Creutzig; G Schellong
Journal:  Onkologie       Date:  1986-04

6.  [Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81].

Authors:  M Schrappe; J Beck; W E Brandeis; H J Feickert; H Gadner; N Graf; W Havers; G Henze; A Jobke; B Kornhuber
Journal:  Klin Padiatr       Date:  1987 May-Jun       Impact factor: 1.349

7.  [Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)].

Authors:  H Riehm; A Reiter; M Schrappe; F Berthold; R Dopfer; V Gerein; R Ludwig; J Ritter; B Stollmann; G Henze
Journal:  Klin Padiatr       Date:  1987 May-Jun       Impact factor: 1.349

8.  Treatment of acute myelogenous leukemia in children.

Authors:  G Schellong; U Creutzig; J Ritter
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

9.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

10.  Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78.

Authors:  U Creutzig; J Ritter; H Riehm; H J Langermann; G Henze; H Kabisch; D Niethammer; H Jürgens; B Stollmann; U Lasson
Journal:  Blood       Date:  1985-02       Impact factor: 22.113
View more
  3 in total

1.  Milestones in the curability of pediatric cancers.

Authors:  Melissa M Hudson; Michael P Link; Joseph V Simone
Journal:  J Clin Oncol       Date:  2014-04-14       Impact factor: 44.544

Review 2.  Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.

Authors:  Melissa M Hudson; Joseph P Neglia; William G Woods; John T Sandlund; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Daniel M Green
Journal:  Pediatr Blood Cancer       Date:  2011-10-28       Impact factor: 3.167

3.  Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia.

Authors:  Sten-Eirik W Jacobsen; Tariq Enver; Christoph Lutz; Petter S Woll; Georgina Hall; Anders Castor; Helene Dreau; Giovanni Cazzaniga; Jan Zuna; Christina Jensen; Sally A Clark; Andrea Biondi; Chris Mitchell; Helen Ferry; Anna Schuh; Veronica Buckle
Journal:  Leukemia       Date:  2012-10-22       Impact factor: 11.528
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.